Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL
2 意见
• 07/14/23
0
0
嵌入
In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论